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Abstract  11 
Statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors that are widely 12 
used for the treatment of hypercholesterolemia. Besides their cholesterol-lowering effect, statins 13 
have been reported to have antiviral activity against a variety of viruses, including hepatitis C virus 14 
(HCV). Several statins inhibit the in vitro replication of subgenomic HCV replicons and also suppress in 15 
vitro RNA replication of infectious HCV. The precise mechanism of the anti-HCV activity of statins has 16 
not yet been defined. Recent studies suggest that the antiviral effect may result from the inhibition 17 
of geranylgeranylation of cellular proteins rather than the inhibition of cholesterol synthesis. Despite 18 
the antiviral effect observed in vitro, statin monotherapy seems to be insufficient for the treatment 19 
of chronic HCV infection. However, several prospective and retrospective studies demonstrated that 20 
the addition of statins to IFN-α and ribavirin therapy increases SVR, RVR, and EVR rates without the 21 
occurrence of additional adverse events. These clinical data, together with the excellent safety 22 
profile and low cost, suggest that statins may play a role in HCV therapy until more potent and safe 23 
direct-acting antivirals become available. 24 
Introduction 25 
Over the last decade, major progress has been made in the discovery of novel antivirals for the 26 
treatment of hepatitis C virus (HCV) infections. In 2011 the first HCV protease inhibitors, telaprevir 27 
and boceprevir, were approved in combination with pegylated interferon (PEG-IFN)-α and ribavirin 28 
(RBV) for the treatment of chronic hepatitis C genotype 1 infections in Europe and the United States. 29 
A number of other direct-acting antivirals (DAA) are in clinical developmental either in combination 30 
with PEG-IFN-α and RBV or with other DAAs in IFN-free regimens (with or without RBV). However, 31 
the use of DAAs may be hampered by (severe) side-effects, the development of resistant variants 32 
and (for some) lack of efficacy against genotypes other than genotype 1. Furthermore, novel DAA 33 
combination therapies will probably not be affordable in the developing world in the foreseeable 34 
future. The addition of low-cost drugs such as statins could thus improve the efficacy of traditional 35 
PEG-IFN/RBV therapy without high additional costs. Several studies have investigated the potential 36 
antiviral activity of statins in patients chronically infected with HCV. To date, the clinical data on the 37 
efficacy of statin therapy in HCV-infected patients are conflicting, making it difficult to estimate the 38 
potential use of statins in future HCV therapy. In this review, the current state of the art on the in 39 
vitro and in vivo anti-HCV activity of statins is summarized and the potential of statins in the 40 
treatment of chronic HCV infection is discussed. 41 
Statins 42 
Statins are the second most commonly prescribed drugs worldwide and are mainly used for 43 
primary and secondary prevention of cardiovascular disease. Besides their cholesterol-lowering 44 
effect, statins also have anti-proliferative, pro-apoptotic, anti-angiogenic, immunomodulatory and 45 
anti-infective effects. Statins inhibit 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase, 46 
the rate-limiting enzyme involved in cholesterol biosynthesis in the liver. HMG-CoA reductase 47 
catalyzes the conversion of HMG-CoA into mevalonic acid (see Figure 1). Therefore, the inhibition of 48 
HMG-CoA reductase by statins results in the reduction of several downstream products of the 49 
mevalonate pathway, such as cholesterol, but also prenyl precursors like farnesyl and geranylgeranyl 50 
pyrophosphate. During post-translational modification steps these prenyl precursors are covalently 51 
attached to various cellular proteins to facilitate their membrane association.  52 
Statins have been reported to possess in vitro antiviral activity against a variety of viruses, such as 53 
HIV-1 [(Giguère and Tremblay, 2004)(del Real et al., 2004)(Amet et al., 2008)], poliovirus (Liu et al., 54 
2006), cytomegalovirus (Potena et al., 2004), dengue virus (Martínez-Gutierrez et al., 2011) and 55 
respiratory syncytial virus (Gower and Graham, 2001). Furthermore, a recent review highlights the 56 
possibility of administration of statins to reduce mortality in the case of an influenza pandemic 57 
(Fedson, 2013). Several statins were also shown to inhibit the replication of subgenomic HCV 58 
replicons (Ikeda et al., 2006) and to suppress RNA replication of infectious HCV (Amemiya et al., 59 
2008). The observed anti-HCV activity of statins suggests that HCV requires elements of the 60 
cholesterol biosynthetic pathway for efficient replication. In other studies it was demonstrated that 61 
HCV has an intimate link with the host lipid metabolism (recently reviewed in (Schaefer et al, 2013)). 62 
HCV virions circulate in the blood in complex with lipoproteins (Thomssen et al., 1992) and 63 
lipoprotein receptors such as the LDL receptor and SR-BI have been reported to be involved in HCV 64 
entry. Furthermore, HCV exploits the VLDL assembly and secretion pathway to be released from 65 
hepatocytes and lipid droplets (LDs) play an important role in HCV virion assembly. 66 
The mechanism by which statins inhibit HCV replication is still unknown. The anti-HCV activity of 67 
statins does not seem to be related to their cholesterol-lowering ability since fluvastatin appears to 68 
be the most active statin in inhibiting in vitro HCV replication (Sezaki et al., 2009) but inhibits HMG 69 
CoA reductase to a lesser extent than other statins (IC50 of 28 nM vs 5-11 nM for atorvastatin, 70 
simvastatin, cerivastatin and rosuvastatin) (Istvan and Deisenhofer, 2001). Furthermore, adding 71 
exogenous cholesterol does not reverse the in vitro antiviral effect of statins, whereas addition of 72 
exogenous geranylgeranyl pyrophosphate (GGpp) does (Kapadia et al, 2005). This confirms that the 73 
anti-HCV activity of statins is not due to the inhibition of cholesterol synthesis but due to the 74 
inhibition of geranylgeranylation of cellular proteins. F-box and leucine rich repeat protein 2 (FBL2) 75 
was identified as a geranylgeranylated host factor essential for HCV replication (Wang et al., 2005). 76 
FBL2 belongs to the family of the F-box proteins and is likely involved in an ubiquitination reaction, 77 
but its substrate(s) are unknown (16). At this moment it is not entirely clear if and how FBL2 is 78 
required for HCV replication and whether it is fully responsible for the antiviral effect of the statins.  79 
In vitro anti-HCV activity of statins 80 
The anti-HCV activity of statins was first described in 2003 (Ye et al., 2003). HCV genotype 1 81 
replicon containing cells were treated with lovastatin to study the involvement of protein and sterol 82 
membrane modifications in viral RNA replication and formation of the viral replication complex. 83 
Administration of 50 µM of lovastatin resulted in a reduction in HCV RNA levels of 70-95%. 84 
In 2006 the different anti-HCV profiles of five statins were characterized (atorvastatin, 85 
fluvastatin, lovastatin, pravastatin and simvastatin) (Ikeda et al., 2006). To this end, the OR6 full 86 
length replicon system (genotype 1b) was used (Ikeda et al., 2005). A range of anti-HCV activities was 87 
described with fluvastatin being the most active inhibitor in the series (IC50 = 0.9 µM). Lovastatin, for 88 
which anti-HCV activity had been demonstrated earlier [(Ye et al., 2003), (Kapadia and Chisari, 89 
2005)], had a more modest antiviral effect (IC50 = 2.2 µM). In contrast, pravastatin, which is also a 90 
known inhibitor of HMG-CoA reductase, did not inhibit HCV replication, suggesting a more complex 91 
mechanism of action than the one previously suggested, namely the inhibition of cholesterol 92 
biosynthesis. Importantly, the authors also demonstrated that combination treatment of fluvastatin 93 
and IFN-α resulted in a synergistic inhibitory effect on the levels of HCV RNA replication in the HCV 94 
genotype 1 replicon system. These data suggest that statins could be used as part of a combination 95 
therapy with the current standard of care. The in vitro activity of a similar panel of statins (comprising 96 
fluvastatin, atorvastatin, mevastatin, simvastatin, lovastatin and pravastatin) was characterized in 97 
2007 (Kim et al., 2007). We further confirmed the anti-HCV activity of several statins (lovastatin, 98 
mevastatin, simvastatin and fluvastatin) in genotype 1b subgenomic replicon cells as well as the 99 
JFH1-CS/N6 HCVcc system (Delang et al., 2009). 100 
Based on the aforementioned studies and depending on the selected in vitro model, the 101 
particular statin selected and the experimental design, the IC50 values of the various statins for the 102 
inhibition of HCV replication were shown to be between 1-10 µM for replicon models and 10-30 µM 103 
for the HCVcc infectious cell culture system. Most of the DAAs in late clinical development, as well as 104 
the two NS3/4A protease inhibitors currently on the market, telaprevir and boceprevir, have IC50 105 
values in the low to medium nanomolar range [(Lam et al., 2012), (Lin et al., 2009), (Malcolm et al., 106 
2006), (Paeshuyse et al., 2006), (Perni et al., 2006), (Wang et al., 2012)]. Based on this it can be 107 
concluded that statins possess only modest antiviral activity in vitro in a monotherapeutic setting.  108 
The possibility of incorporating statins in anti-HCV combination therapy has been investigated by 109 
several groups in an in vitro setting. Treatment of OR6 HCV replicon cells with a statin (atorvastatin, 110 
lovastatin, simvastatin or fluvastatin) in combination with IFN-α resulted in a substantially increased 111 
antiviral effect when compared to IFN-α alone (Ikeda et al., 2006). This additive effect was confirmed 112 
by our group for combinations of simvastatin or mevastatin with IFN-α (Delang et al., 2009). In 113 
addition selected inhibitors of viral HCV replication were combined with these two statins: the NS5B 114 
inhibitors 4’-azidocytidine (R1479), benzothiadiazine GSK-4 and benzofuran HCV-796, as well as the 115 
NS3/4A protease inhibitor VX-950 (telaprevir). An additive antiviral effect was observed when 116 
mevastatin or simvastatin was combined with any of these inhibitors. Furthermore, mevastatin was 117 
also able to delay or even prevent the emergence of escape mutants to the non-nucleoside RNA 118 
polymerase inhibitor HCV-796. A synergistic antiviral effect of simvastatin in combination with IFN-α 119 
in a genotype 1b subgenomic replicon system was also reported (Amemiya et al., 2008). These in 120 
vitro data suggest that statins may have the potential to (i) increase the efficacy of current or future 121 
HCV therapy and (ii) delay the development of resistance against HCV direct-acting antivirals (DAA).  122 
Do statins decrease HCV RNA levels in HCV-infected patients? 123 
a) Monotherapy 124 
In the first clinical trials the potential of statins as antiviral agents for the treatment of HCV was 125 
studied in a monotherapeutic setting. Initial pilot clinical trials showed mixed results. In 2007, 10 126 
HCV-infected patients in need of cholesterol-lowering treatment were treated with 20 mg/day of 127 
atorvastatin for a period of 12 weeks; HCV RNA levels were measured by PCR at weeks 4 and 12 128 
(O’Leary et al., 2007). When comparing pretreatment HCV RNA levels to HCV RNA levels at weeks 4 129 
or 12, no significant difference was observed. In contrast to this first study, in a small trial conducted 130 
in 2008 (n = 22), the authors reported transient, 0.5 log10 reductions in HCV RNA levels in 50% of 131 
patients treated with 20-80 mg/day of fluvastatin over a period of 12 weeks, suggesting for the first 132 
time that statins can inhibit HCV replication in infected patients (Bader et al., 2008). 133 
Further studies investigating the efficacy of statin monotherapy were conducted and reported 134 
largely negative results: a cross-sectional and longitudinal analysis of the response of chronically 135 
HCV-infected veterans undergoing statin treatment (n=50) was unable to demonstrate an association 136 
between simvastatin therapy and HCV RNA levels (Forde, 2009). A prospective cohort study also 137 
failed to document significant changes in HCV RNA levels after 12 weeks of rosuvastatin treatment in 138 
11 chronic HCV-infected patients (Patel et al., 2011). Furthermore, a significant increase in HCV RNA 139 
levels was observed in 59% of HIV-HCV co-infected patients after 4 weeks of 80 mg/day fluvastatin 140 
treatment (Milazzo et al., 2009). These findings lend credence to the hypothesis that statins may 141 
actually induce a pro-viral state in vivo, possibly due to the up-regulation of lipoprotein receptors 142 
such as low density lipoprotein receptor (LDLR), compensating for the antiviral effects seen in vitro. 143 
However, this hypothesis has not been confirmed in in vitro or in vivo studies.  In contrast, our 144 
unpublished results show no increase of HCV particle uptake in human hepatoma cells following 145 
statin treatment. Further studies are required to clarify this matter.  146 
From the above it is clear that statin monotherapy results, at best, in some decrease of viral 147 
replication. The modest activity or even lack of an antiviral effect is in stark contrast with the in vitro 148 
anti-HCV activity of some of the statins. This might be explained by unfavorable pharmacokinetics 149 
whereby concentrations required for antiviral activity in vitro are not reached in serum following 150 
prolonged conventional dosing (20-80 mg/day). For example, the 20 mg daily dose of atorvastatin 151 
used in the O’Leary study  coincides with a peak serum concentration of 2.5 x 10-3 µM (O’Leary et al., 152 
2007), which is well below the reported in vitro activity range of 1-10 µM. However, as the 153 
replication of HCV occurs predominantly in the liver, intrahepatic concentrations of statins may be 154 
more relevant than plasma concentrations. Although the thesis that statin concentrations are likely 155 
much higher in the human liver than in plasma is widely accepted, there are, to the best of our 156 
knowledge, no studies published in which concentrations of statins in the human liver have been 157 
determined. In rats, the liver concentration of lovastatin is 15 to 18-fold higher than the 158 
concentration in blood and other tissues (Nezasa et al., 2002; Tse et al., 1990; Zhang and Yang, 2007). 159 
If one would assume that liver concentrations of statins in the human liver may also be ≈ 15-fold 160 
higher than in plasma, a very rough estimation would suggest concentrations of 0.75-15 µM in the 161 
human liver (depending on the pharmacokinetic profile of the specific statin). Despite the mostly 162 
negative results of statin monotherapy in vivo, in vitro studies have shown additive, sometimes 163 
synergistic, effects of adding statins to the IFN-based standard of care and DAA regimens. It is 164 
therefore worth investigating the potential clinical role of statins as a component of anti-HCV 165 
combination therapy. 166 
b) Combination therapy 167 
When investigating the antiviral efficacy of statins as a part of combination therapy it is 168 
important to distinguish between two different types of studies. On the one hand, a series of 169 
retrospective cohort studies have been carried out on patients already taking statins to investigate 170 
whether there is a correlation between previous statin use and the efficacy of anti-HCV therapy. A 171 
second type of study involves prospective, randomized controlled trials in which a subset of patients 172 
are given statins during a set time period to assess whether or not statins improve efficacy of anti-173 
HCV therapy. 174 
i) Retrospective cohort studies – patients already taking statins 175 
In a retrospective study of the IDEAL (Individualized Dosing Efficacy Versus Flat Dosing to Assess 176 
Optimal Pegylated Interferon Therapy) trial, concomitant statin use (comprising many different 177 
statins, namely atorvastatin, pravastatin, simvastatin, rosuvastatin, lovastatin and fluvastatin) was 178 
found to be a statistically significant positive predictor of sustained virological response (SVR) in HCV 179 
genotype 1 infected patients treated with PEG-IFN/RBV (Harrison et al., 2010). SVR is defined as 180 
undetectable HCV RNA levels 24 weeks after the cessation of treatment. Statin use was associated 181 
with a SVR rate of 53%, as compared to non-statin users who achieved an average SVR rate of 39% (p 182 
= 0.02). Importantly, this study also showed that there was no significant difference in serious 183 
adverse events between statin users and non-statin users. Furthermore, a lower discontinuation rate 184 
was reported in the statin user population (38% vs 46% in non-statin users). It should be noted, 185 
however, that only a small proportion of the total study population was treated with statins (n = 66 186 
vs total n = 3070). 187 
Another retrospective analysis of the US Veteran Affairs administrative database investigated 188 
multiple predictors of SVR in HCV-infected diabetic patients treated with PEG-IFN/RBV (n = 8293) 189 
(Rao and Pandya, 2011). Statins were taken by 10.8% of the cohort, of which simvastatin was the 190 
most commonly used statin (89%). In a multivariate analysis, concomitant statin use emerged as one 191 
of the most positive predictors of SVR in the main cohort studied (OR = 1.39; p = 0.0007). 192 
Additionally, statin use remained a positive predictor in the diabetic patient cohort (20% of the 193 
enrolled patients had diabetes mellitus type 2) included in the study (OR = 1.56; p = 0.0124). This 194 
study provides a strong, albeit retrospective, indication that statins can be effectively implemented 195 
as “adjuvants” to PEG-IFN/RBV combination therapy. Furthermore, statin use appears to be 196 
associated with increased SVR in patients with diabetes mellitus type 2, which is in itself a negative 197 
predictor of SVR [(Elgouhari et al., 2009)(Konishi et al., 2007)(McHutchison et al., 2009)(Romero-198 
Gómez et al., 2005)]. These data highlight for the first time a potential additional role of statins in the 199 
treatment of diabetes patients chronically infected with HCV. 200 
A caveat that requires mentioning when trying to discern a relationship between statin use and 201 
antiviral efficacy is the potential confounding effect of the IL28B genotype. It is well established that 202 
the rs12979860 CC single nucleotide polymorphism in the IL28B gene is associated with increased 203 
SVR rates when patients are treated with IFN-based therapy [(Ge et al., 2009)(Domagalski et al., 204 
2013)(Ragheb et al., 2013)]. Furthermore, this same polymorphism is also associated with increased 205 
serum cholesterol levels in HCV-infected patients (Li et al., 2010). Therefore, patient groups that 206 
already take statins as a result of high serum cholesterol, also have a higher chance of possessing the 207 
rs12979860 CC IL28B SNP and responding more positively to IFN-based antiviral therapy as a result. 208 
ii) Prospective studies 209 
The first prospective trial investigating the antiviral efficacy of a statin in combination with PEG-210 
IFN/RBV was conducted in 2009 (Sezaki et al., 2009). In a small pilot trial (n = 21) HCV genotype 1b 211 
infected patients were administered triple therapy consisting of PEG-IFN/RBV and 20 mg/day 212 
fluvastatin administered over a period of 48 weeks. The authors observed a SVR rate of 67%. In 213 
comparison, earlier studies of the same patient population where patients received only PEG-214 
IFN/RBV for 48 weeks reported SVR rates of 47-50%. Due to the small number of patients included in 215 
this trial, however, no statistically significant differences could be attained. Nonetheless, this study 216 
provided an important impetus in the undertaking of further clinical trials to investigate the potential 217 
role of statins in anti-HCV combination therapy. 218 
A randomized controlled trial was carried out in 2010 in which 45 patients were treated with 219 
either PEG-IFN/RBV or PEG-IFN/RBV in combination with 80 mg/day of fluvastatin and tested for the 220 
presence of HCV RNA after 4, 12 and 24 weeks of treatment (Milazzo et al., 2010). In the PEG-221 
IFN/RBV + fluvastatin arm a SVR rate of 38% was reported as compared to a SVR rate in the PEG-222 
IFN/RBV arm of 13%; however this difference was not statistically significant (p = 0.08). Interestingly, 223 
however, a statistically significant difference in the RVR rate (rapid virological response; defined as 224 
negative HCV RNA after 4 weeks of treatment) was reported (33% vs 4%; p = 0.02).  225 
A larger randomized controlled trial allocated 101 chronic HCV-infected patients (all infected with 226 
HCV genotype 1b) to either a PEG-IFN/RBV treatment arm or a PEG-IFN/RBV + fluvastatin 227 
(administered at 20 mg/day) treatment arm for a period of 48-72 weeks (Kondo et al., 2012). The SVR 228 
rates achieved in the treatment arms were 41.7% and 63%, respectively (p = 0.04). To our 229 
knowledge, this is the first randomized controlled study to demonstrate a statistically significant 230 
improvement in SVR rate upon addition of fluvastatin to an IFN-RBV treatment regimen. The authors 231 
suggested that statins can be considered as a second line treatment in the event that patients do not 232 
tolerate protease inhibitor-based therapies. A retrospective analysis of this study indicated that the 233 
mechanism by which fluvastatin increased SVR rates was related to the inhibition of viral relapse, 234 
although no biological mechanism for this effect has been proposed (Atsukawa et al., 2013). A more 235 
recent meta-analysis of several randomized controlled trials concluded that statins significantly 236 
increase SVR rates in combination with PEG-IFN/RBV therapy when administered to patients infected 237 
with HCV genotype 1 (Zhu et al., 2013). A summary of the studies discussed above is included in 238 
Table 1. 239 
Various studies have shown a correlation between HCV infection and decreased serum 240 
lipoprotein levels [(Serfaty et al., 2001)(Petit, 2003)(Siagris et al., 2006)(Hsu et al., 2008)]. The 241 
etiology of this hypocholesterolemia is not yet fully understood and is postulated to be either the 242 
result of altered lipid metabolism (most likely related to VLDL secretion) in virus infected hepatocytes 243 
or hepatic damage resulting from hepatitis (Honda and Matsuzaki, 2011). HCV-associated lipid 244 
perturbations also appear to be dependent on HCV genotype. Hypocholesterolemia and steatosis are 245 
both strongly associated with HCV genotype 3 infection [(Quadri et al., 2000)(Hui et al., 2002)] and 246 
further studies have shown that HCV genotype 3 selectively modulates the cholesterol synthesis 247 
pathway [(Jackel-Cram et al., 2010)(Clark et al., 2012)]. Given the fact that statins interact with the 248 
same biochemical pathway, their antiviral efficacy may also be genotype-dependent. This genotype 249 
variability has not yet been adequately studied, given the fact that most clinical studies to date have 250 
been conducted on patients infected with HCV genotype 1 [(Kondo et al., 2012)(Kohjima et al., 251 
2013)]. A recent prospective study investigating treatment efficacy of added FLV to PEG-IFN/RBV 252 
therapy in genotype 1 and genotype 3 patients reported no significant increase in SVR rates in the 253 
genotype 3 patient population, in contrast to genotype 1 patients with a high viral load, indicating 254 
that the antiviral efficacy of statins may indeed be genotype-dependent (Kurincic et al., 2014). 255 
Is the use of statins safe in patients with liver disease? 256 
An important issue facing the implementation of statins as antiviral drugs is the perceived risk of 257 
administering lipid lowering drugs to patients with acute or chronic liver disease. Concerns regarding 258 
statin safety were raised when cerivastatin was withdrawn from the market in 2001 due to an 259 
increased frequency of drug-related rhabdomyolysis and subsequent kidney failure, resulting in 52 260 
deaths worldwide (Furberg and Pitt, 2001). While these side-effects have also been described for the 261 
other statins still on the market, they are considerably rarer and estimated to occur at a rate of only 262 
1-3 cases per 100,000 patient years (Law and Rudnicka, 2006). It is therefore generally accepted that 263 
the benefits of statin treatment as lipid-lowering therapy far outweigh the risks of severe adverse 264 
events and that statins can be considered as an extremely safe class of drugs. 265 
The safety issues associated with the administration of statins to patients with chronic/acute 266 
liver disease, however, have been more complicated. Statin treatment can be accompanied by 267 
moderate increases in serum ALT and AST values but these effects are generally transient and are not 268 
considered to be clinically relevant (Tolman, 2000). In addition, while isolated case reports of statin-269 
related hepatoxicity have been described (Clarke and Mills, 2006; Kinnman and Hultcrantz, 2001), 270 
these events are extremely rare and no clear association between statin use and the onset of liver 271 
disease has yet been reported (de Denus et al., 2004; Law and Rudnicka, 2006). Several studies have 272 
been conducted to investigate the safety profile of statins in patients chronically infected with HCV. 273 
No significant elevations in ALT or AST could be measured in 17 HCV-infected patients taking 274 
simvastatin (Gibson and Rindone, 2005). A larger study was carried out in which changes in liver 275 
enzymes were investigated over a 12-month period in three distinct patient cohorts: i) HCV-infected 276 
patients not undergoing statin therapy, ii) HCV-infected patients undergoing statin therapy and iii) 277 
non HCV-infected patients undergoing statin therapy (Khorashadi et al., 2006). Importantly, while 278 
statin therapy in HCV-infected patients was associated with a greater incidence of mild-moderate 279 
increases in liver enzymes as compared to HCV-infected patients not undergoing statin therapy, 280 
these increases were not found to be significantly different to the liver enzyme elevations measured 281 
in non HCV-infected patients undergoing statin therapy. This seems to suggest that HCV-infected 282 
patients taking statins are at no greater risk of hepatotoxicity as compared to uninfected 283 
hyperlipidemic patients i.e. the main patient population taking a statin.  284 
While these studies support the postulation that statin therapy is safe in HCV-infected patients it 285 
is important to note that many of these studies were undertaken to assess safety of statin therapy 286 
for the purpose of lowering LDL levels. The optimal dosage regime required for the successful 287 
treatment of HCV may be different and it is important to assess the safety of statin treatment in this 288 
setting as well. Nevertheless, these studies provide evidence that statin treatment should be 289 
considered safe in HCV-infected patients. 290 
Given the fact that HCV-infection is associated with hypocholesterolemia it is possible that 291 
further lowering cholesterol levels with statin add-on therapy may exacerbate side-effects associated 292 
with this disorder. This would be especially relevant in patients infected with HCV genotype 3, given 293 
the stronger association of this genotype with perturbations in lipoprotein levels. A notable side- 294 
effect in this regard is depression; several studies have reported an inverse correlation between 295 
serum cholesterol levels and the incidence of depression and suicidal ideation in both population and 296 
primary care settings (reviewed in Sansone and Sansone, 2008). More recent studies have also 297 
demonstrated that chronic HCV infection itself [(Carta et al., 2012)(Lee et al., 2013)] as well as 298 
interferon-based anti-HCV therapy (Udina et al., 2012) are both associated with an increased 299 
incidence of depression in HCV-infected patients. Given these data it is tempting to conclude that 300 
cholesterol-lowering statin add-on therapy would further increase the risk of depression in chronic 301 
HCV patients already taking interferon-based therapy. However, the effects of statins themselves on 302 
the incidence of depression remain unclear, as shown by a recent meta-analysis of 7 studies 303 
surrounding this topic in which an anti-depressive effect of statin therapy was reported (Parsaik et 304 
al., 2013). Further studies are certainly warranted to ascertain what the effect will be of adding 305 
statins to established anti-HCV therapy regarding the incidence of depression in chronic HCV 306 
patients. 307 
When proposing a role for statins in anti-HCV combination therapy, it is important to take 308 
potential drug-drug interactions into account. Statins are documented cytochrome P450 (CYP) 309 
isoenzyme substrates, the extent of metabolism varying for each statin (Causevic-Ramosevac and 310 
Semiz, 2013). Lovastatin, simvastatin and atorvastatin are primarily metabolized by CYP3A4 and are 311 
most prone to drug-drug interactions with CYP3A4 inhibitors, which can increase the risk of statin-312 
associated adverse events. Both anti-HCV protease inhibitors currently on the market, boceprevir 313 
and telaprevir, are potent inhibitors of CYP3A4 and are thus especially prone to drug-drug 314 
interactions (Kiser et al., 2013). Telaprevir has been shown to substantially increase the plasma 315 
concentrations of atorvastatin in patients (Lee et al., 2011). Statin-associated adverse events have 316 
been described for patients taking HIV protease inhibitors, which are also potent CYP3A4 inhibitors 317 
(Schmidt et al., 2007). For this reason, lovastatin,  simvastatin and to some extent atorvastatin are 318 
generally contraindicated for concomitant use with telaprevir or boceprevir (Burger et al., 2013; 319 
Chauvin et al., 2013; Teixeira et al., 2013). It is important to note, however, that the most active 320 
statin in vitro, fluvastatin, is primarily metabolized via CYP2D9 and, along with pravastatin, is 321 
generally considered safe for combination with CYP3A4 inhibitors (Causevic-Ramosevac and Semiz, 322 
2013; Chauvin et al., 2013). The CYP inhibition profile will have to be carefully ascertained for the 323 
newer anti-HCV drugs in late clinical development in order to assess the potential for statin 324 
combination therapy.  325 
Perspectives 326 
With new and highly efficacious DAAs approaching market approval, future prospects for the 327 
treatment of patients with chronic HCV infection appear favorable. Nevertheless, an issue which is 328 
easily forgotten in this regard is the rising cost of DAA-based combination therapy. Telaprevir- and 329 
boceprevir-based therapies are estimated to cost up to $50,000 per treatment course, with the 330 
protease inhibitor comprising almost half of this amount (Gellad et al., 2012), 331 
(http://www.hepatitiscnewdrugresearch.com/cost-of-treating-with-telaprevir.html, last consulted: 332 
19-02-2014) and drugs such as Sofosbuvir (Gilead) and Simeprevir (Johnson & Johnson) are at least as 333 
expensive. While developed nations may be able to afford these costly regimens, the situation is 334 
drastically different in the developing world. A significant portion of HCV-infected patients worldwide 335 
require treatment in a limited resource setting and will most likely not benefit from expensive DAA-336 
based therapies in the immediate future. Adding statins to the established IFN-based combination 337 
therapy in these countries, where applicable, could serve to increase SVR rates until the time that the 338 
newer, more efficacious DAAs become available and affordable. The patents for fluvastatin, 339 
atorvastatin, simvastatin and lovastatin have expired and all these drugs are currently available as 340 
generics, substantially lowering their cost. A recent report published by the WHO also suggested a 341 
role for statins in the treatment of cardiovascular disease in developing nations, indicating 342 
administration of these drugs in resource limited countries is indeed feasible (Prevention and Control 343 
of Noncommunicable Diseases: Guidelines for primary health care in low-resource settings, WHO 344 
report, 2012).  Additionally, while this WHO report investigated the use of statins in a cardiovascular 345 
disease setting, treatment duration for anti-HCV therapy would be substantially shorter, typically 346 
limited to 12-24 weeks, which would decrease the costs of administering statins for this indication in 347 
developing nations. 348 
Statins possess only modest anti-HCV activity in vitro and appear ill-suited as an anti-HCV drug 349 
administered as monotherapy to HCV-infected patients. However, in combination with IFN-based 350 
therapy, significant increases in SVR rates can be achieved. This does not seem sufficient, however, 351 
to justify including statins in future DAA-based combination regimens, particularly when taking into 352 
account that a series of promising combinations of direct-acting HCV drugs will achieve market 353 
approval in the coming years. However, the excellent safety profile of statins, the availability of 354 
generics as well as the high cost of current and future DAAs are factors which highlight the potential 355 
of statins in resource limited settings. Furthermore, as statins could be able to improve SVR rates at 356 
an affordable cost, these drugs may fulfill an important role in “bridging the gap” until more potent 357 
and cheaper DAAs become available. 358 
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 Table 1: Overview of clinical studies investigating use of statins as antiviral agents against HCV 597 
 598 
MONOTHERAPY 
Author 
(year) 
Study design No. of 
patients 
HCV genotype 
(n) 
Statin use, dose (n) Control Duration 
(weeks) 
Outcome 
O’Leary et al 
(2007) 
Prospective study  10 1 (8) 
2 (1) 
4 (1) 
Atorvastatin,  
20 mg/day (10) 
NA 12 No correlation 
between atorvastatin 
use and post-
treatment HCV RNA 
levels 
Bader et al 
(2008) 
Prospective study 
 
31 1 (15) 
2 (9) 
3 (7) 
Fluvastatin,  
20-80 mg/day (10) 
NA 12 Transient 0.5log10 
reductions in 50% of 
patients after 
fluvastatin treatment 
Forde et al 
(2009) 
Retrospective 
cohort study 
50 1 (34) 
2 (4) 
3 (1) 
Not typed (1) 
Simvastatin, NA (42) 
Lovastatin, NA (5) 
Pravastatin, NA (2) 
Fluvastatin, NA (1) 
NA  No correlation 
between statin use and 
post-treatment HCV 
RNA levels 
Patel et al 
(2011) 
Prospective 
cohort study 
11 1 (11) Rosuvastatin,  
20-40 mg/day (11) 
NA 12 No correlation 
between rosuvastatin 
use and post-
treatment HCV RNA 
levels  
Milazzo et al 
(2009) 
Randomized 
controlled study 
43 1 (43) 
*HIV coinfection 
Fluvastatin 
80 mg/day (22) 
Control arm: no 
treatment (21) 
4 Positive correlation 
between statin use and 
post-treatment HCV 
RNA levels (p = 0.032) 
COMBINATION THERAPY 
I. Retrospective cohort studies: patients already taking statins 
Author 
(year) 
Study design No. of 
patients 
HCV genotype 
(n) 
Statin use, dose (n) Combination 
regimen (n)  
Duration 
(weeks) 
Outcome 
Harrison et 
al (2010) 
Retrospective 
data analysis 
3070 1 (3070) Atorvastatin, NA (29) 
Pravastatin, NA (14) 
Simvastatin, NA (10) 
Rosuvastatin, NA (6) 
Lovastatin, NA (5) 
Fluvastatin, NA (1) 
Ezetimibe/simvastatin, NA (1) 
+ PEG-IFN alfa2b, 
1.5 µg/kg/RBV 
(22) 
 
+ PEG-IFN alfa2b,  
1 µg/kg/RBV (22) 
 
+ PEG-IFN alfa2a 
/RBV (22) 
48 Positive association 
between statin use and 
SVR rate  
(p = 0.02) 
Rao and 
Pandya 
(2011) 
Retrospective 
data analysis 
8293 Unknown Simvastatin, NA (798) 
Others , NA (99) 
+ PEG-IFN/RBV 
(8293) 
- Positive association 
between statin use and 
SVR rate  
(p = 0.0007) 
II. Prospective studies 
Sezaki et al 
(2009) 
Prospective study 
 
21 1b (21) Fluvastatin, 20 mg/day (21) + PEG-IFN/RBV 
(21) 
48 No statistically 
significant association 
between statin use and 
SVR rate 
Milazzo et al 
(2010) 
Randomized 
controlled study 
44 1 (44) Fluvastatin, 80 mg/day (22) + PEG-IFN/RBV 
(44) 
24 Positive association 
between statin use and 
RVR rate (33% vs. 4%; p 
= 0.02) 
Kondo et al 
(2012) 
Randomized 
controlled study 
94 1b (94) Fluvastatin, 20 mg/day (46) + PEG-IFNalfa2b  
1.5 µg/kg/week  
/ RBV 600-1000 
mg/day (94) 
48-72 Positive association 
between statin use and 
SVR rate (63% vs. 
41.7%;  
p = 0.04) 
